비교리스트

 카트 문의
시장보고서
상품코드
1566980

빈카 알칼로이드 화합물 시장 : 제품 유형별, 최종 사용자별 - 세계 기회 분석 및 산업 전망(2024-2033년)

Vinca Alkaloid Compounds Market By Product Type (Vinblastine, Vincristine, Vindesine) , By End User (Hospitals, Clinics, Academic & Research Institutes) : Global Opportunity Analysis and Industry Forecast, 2024-2033
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 280 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

빈카 알칼로이드 화합물 시장

빈카 알칼로이드 화합물 시장은 2023년 8,100만 달러로 평가되며 2024-2033년 연평균 7.2% 성장하여 2033년에는 1억 6,150만 달러에 달할 것으로 예상됩니다.

빈카 알칼로이드는 자연적으로 존재하는 이차 대사 산물로, 주로 시소과 식물인 카타란투스 로즈에서 추출됩니다. 이 화합물은 항유사분열 및 항미세관 특성으로 활용되고 있습니다. 세포분열 시 빈카 알칼로이드 화합물은 세포분열을 구조적으로 지지하는 데 필요한 단백질인 β-튜브린의 중합을 억제합니다. 이러한 저해는 세포 독성과 세포 사멸을 초래합니다. 이 화합물의 특성은 림프종, 백혈병, 유방암, 폐암 등 다양한 암 치료제로 활용되고 있습니다.

다양한 암의 유병률 증가와 치료의 신흥 시장 개척은 빈카 알칼로이드 화합물 시장의 중요한 촉진요인입니다. 또한, 암 완화를 위한 치료 및 치료 솔루션 개발을 위한 끊임없는 연구 개발 노력은 빈카 알칼로이드 화합물에 대한 수요를 증가시키고 있습니다. 내생식물을 이용한 2차 대사산물의 합성은 향후 중요한 트렌드가 될 것으로 예상됩니다. 식물에서 직접 빈카 알칼로이드 화합물을 추출하는 것은 매우 비효율적이고 복잡합니다. 이와는 대조적으로, 엔도파이트의 미생물 발효 과정은 상당히 실현 가능하고 유능한 절차이며, 향후 몇 년동안 항암제 생산을 촉진하고 촉진할 것으로 예상됩니다.

그러나 신경독성, 골수 억제 등 빈카 알칼로이드 화합물의 잠재적 부작용이 심각합니다. 이 때문에 화합물의 사용이 어느 정도 제한되어 시장 개척을 억제하고 있습니다. 또한 빈카 알칼로이드 화합물에서 유래한 약물은 장기간 사용하면 종양세포가 내성을 갖게 되어 장기적인 효능이 저하되어 시장 개척에 걸림돌이 되고 있습니다. 반대로 시장 개척의 기술 혁신으로 빈카 알칼로이드 화합물의 항암 작용을 활용하고 그 한계를 제거함으로써 시장 확대에 유리한 기회를 가져오고 있습니다. 예를 들어, National Library of Medicine에 게재된 연구 논문에 따르면, 빈카 알칼로이드 화합물의 부작용은 다른 화학요법과 병용요법을 통해 완화되어 칵테일 약물의 항종양 효과를 높인 것으로 나타났습니다.

부문별 리뷰

빈카 알칼로이드 화합물 시장은 제품 유형, 최종 사용자, 지역으로 구분됩니다. 제품 유형별로 시장은 빈브라스틴, 빈크리스틴, 빈데신으로 나뉩니다. 최종 사용자별로 병원, 클리닉, 학술 및 연구 기관으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 분석됩니다.

주요 조사 결과

제품 유형별로는 빈 크리스틴 부문이 2023년 시장을 장악했습니다.

최종 사용자별로는 병원 부문이 2023년 높은 시장 점유율을 차지했습니다.

지역별로는 북미가 2023년 가장 높은 수익을 올릴 것으로 예상됩니다.

본 보고서의 커스터마이징 가능성(추가 비용 및 일정이 필요합니다.)

  • 규제 가이드라인
  • 고객의 관심사에 따른 기업 프로파일 추가
  • 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
  • 기업 프로파일 확대 목록
  • 과거 시장 데이터
  • 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 구도

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 기회
    • 주요 성공 전략
  • Porter의 Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회

제4장 빈카알칼로이드 화합물 시장 : 제품 유형별

  • 시장 개요
  • Vinblastine
  • Vincristine
  • Vindesine

제5장 빈카알칼로이드 화합물 시장 : 최종사용자별

  • 시장 개요
  • 병원
  • 클리닉
  • 학술연구기관

제6장 빈카알칼로이드 화합물 시장 : 지역별

  • 시장 개요
  • 북미
    • 주요 시장 동향과 기회
    • 미국 빈카알칼로이드 화합물 시장
    • 캐나다 빈카알칼로이드 화합물 시장
    • 멕시코 빈카알칼로이드 화합물 시장
  • 유럽
    • 주요 시장 동향과 기회
    • 독일 빈카알칼로이드 화합물 시장
    • 프랑스 빈카알칼로이드 화합물 시장
    • 영국 빈카알칼로이드 화합물 시장
    • 이탈리아 빈카알칼로이드 화합물 시장
    • 스페인 빈카알칼로이드 화합물 시장
    • 기타 유럽 빈카알칼로이드 화합물 시장
  • 아시아태평양
    • 주요 시장 동향과 기회
    • 일본 빈카알칼로이드 화합물 시장
    • 중국 빈카알칼로이드 화합물 시장
    • 호주 빈카알칼로이드 화합물 시장
    • 인도 빈카알칼로이드 화합물 시장
    • 한국 빈카알칼로이드 화합물 시장
    • 기타 아시아태평양 빈카알칼로이드 화합물 시장
  • 라틴아메리카/중동 및 아프리카
    • 주요 시장 동향과 기회
    • 브라질 빈카알칼로이드 화합물 시장
    • 사우디아라비아 빈카알칼로이드 화합물 시장
    • 남아프리카공화국 빈카알칼로이드 화합물 시장
    • 기타 라틴아메리카/중동 및 아프리카 빈카알칼로이드 화합물 시장

제7장 경쟁 구도

  • 서론
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝(2023년)

제8장 기업 개요

  • Accord Healthcare Limited
  • Eli Lilly And Company.
  • Fresenius Kabi AG
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Medline Industries, LP.
  • Pfizer Inc.
  • Pierre Fabre S.A
  • Talon Pharmaceuticals
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
LSH 24.10.29

Vinca Alkaloid Compounds Market

The vinca alkaloid compounds market was valued at $81.0 million in 2023 and is projected to reach $161.5 million by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

Vinca alkaloid is a naturally occurring secondary metabolite, majorly extracted from the periwinkle plant Catharanthus roseus. The compound is utilized for its anti-mitotic and anti-microtubule properties. During cell division, vinca alkaloid compounds block the polymerization of beta-tubulin, a protein necessary to provide structural support during cell division. This blockage results in cytotoxicity and cell death. This property of the compounds is utilized as a therapeutic approach for the treatment of various cancers, including lymphomas, leukemias, breast cancer, and lung cancer.

Increase in the prevalence of various cancer forms and advancements in the development of therapeutic drugs are the significant drivers of the vinca alkaloid compounds market. Furthermore, constant R&D efforts toward the generation of medications and treatment solutions for the mitigation of cancer boost the demand for vinca alkaloid compounds. The synthesis of this secondary metabolite using endophytes is projected to be a significant trend in the future. Extraction of vinca alkaloid compounds directly from the plant is highly inefficient and intricate. Contrarily, the process of microbial fermentation of endophytes is a notably feasible and competent procedure, which is anticipated to facilitate and boost the production of anti-cancer drugs in upcoming years.

However, the potential side-effects of vinca alkaloid compounds are severe, including neurotoxicity and myelosuppression. This limits the usage of compounds to a certain extent, hence restraining the development of the market. Moreover, the tumor cells develop a resistance to the drugs derived from vinca alkaloid compounds over long durations, lowering their long-term efficacy and hampering the market growth. On the contrary, innovations in drug development have led to the harnessing of anti-cancerous properties of vinca alkaloid compounds by eliminating their limitations, presenting lucrative opportunities for the expansion of the market. For instance, according to a research paper published on the National Library of Medicine, the side-effects of vinca alkaloid compounds are mitigated using combination therapy, in which the compound is combined with some other chemotherapy drug, enhancing the anti-tumor effect of the cocktail drug.

Segment Review

The vinca alkaloid compounds market is segmented into product type, end user, and region. On the basis of product type, the market is divided into vinblastine, vincristine, and vindesine. As per end user, it is classified into hospitals, clinics, and academic & research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the vincristine segment dominated the market in 2023.

As per end user, the hospitals segment accounted for a high market share in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global vinca alkaloid compounds market include Accord Healthcare Limited, Eli Lilly and Company., Fresenius Kabi AG, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Medline Industries, LP., Pfizer Inc., Pierre Fabre S.A, Talon Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Viatris Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Vinblastine
  • Vincristine
  • Vindesine

By End User

  • Hospitals
  • Clinics
  • Academic Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Accord Healthcare Limited
    • Eli Lilly and Company.
    • Fresenius Kabi AG
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Medline Industries, LP.
    • Pfizer Inc.
    • Pierre Fabre S.A
    • Talon Pharmaceuticals
    • Teva Pharmaceutical Industries Limited
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VINCA ALKALOID COMPOUNDS MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Vinblastine
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Vincristine
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Vindesine
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: VINCA ALKALOID COMPOUNDS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Academic Research Institutes
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: VINCA ALKALOID COMPOUNDS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Vinca Alkaloid Compounds Market
      • 6.2.5.1. Market Size and Forecast, By Product Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Vinca Alkaloid Compounds Market
      • 6.2.6.1. Market Size and Forecast, By Product Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Vinca Alkaloid Compounds Market
      • 6.2.7.1. Market Size and Forecast, By Product Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Vinca Alkaloid Compounds Market
      • 6.3.5.1. Market Size and Forecast, By Product Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Vinca Alkaloid Compounds Market
      • 6.3.6.1. Market Size and Forecast, By Product Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Vinca Alkaloid Compounds Market
      • 6.3.7.1. Market Size and Forecast, By Product Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Vinca Alkaloid Compounds Market
      • 6.3.8.1. Market Size and Forecast, By Product Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Vinca Alkaloid Compounds Market
      • 6.3.9.1. Market Size and Forecast, By Product Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Vinca Alkaloid Compounds Market
      • 6.3.10.1. Market Size and Forecast, By Product Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Vinca Alkaloid Compounds Market
      • 6.4.5.1. Market Size and Forecast, By Product Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Vinca Alkaloid Compounds Market
      • 6.4.6.1. Market Size and Forecast, By Product Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Vinca Alkaloid Compounds Market
      • 6.4.7.1. Market Size and Forecast, By Product Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Vinca Alkaloid Compounds Market
      • 6.4.8.1. Market Size and Forecast, By Product Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Vinca Alkaloid Compounds Market
      • 6.4.9.1. Market Size and Forecast, By Product Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Vinca Alkaloid Compounds Market
      • 6.4.10.1. Market Size and Forecast, By Product Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Vinca Alkaloid Compounds Market
      • 6.5.5.1. Market Size and Forecast, By Product Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Vinca Alkaloid Compounds Market
      • 6.5.6.1. Market Size and Forecast, By Product Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Vinca Alkaloid Compounds Market
      • 6.5.7.1. Market Size and Forecast, By Product Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Vinca Alkaloid Compounds Market
      • 6.5.8.1. Market Size and Forecast, By Product Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Accord Healthcare Limited
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Eli Lilly And Company.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Fresenius Kabi AG
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Medline Industries, LP.
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Pfizer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Pierre Fabre S.A
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Talon Pharmaceuticals
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Teva Pharmaceutical Industries Limited
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Viatris Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제